Additional Evidence Persuades England To Reimburse Hemophilia Drug Altuvoct

The health technology assessment institute, NICE, has reversed its rejection of Sobi’s once-weekly drug for preventing and treating severe hemophilia A, meaning that the treatment has now secured reimbursement in three European countries.